Aditxt (ADTX) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 13, 2022
Document Information Line Items
Entity Registrant Name	Aditxt, Inc.
Trading Symbol	ADTX
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		44,725,838
Amendment Flag	false
Entity Central Index Key	0001726711
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39336
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-3204328
Entity Address, Address Line One	737 N. Fifth Street
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Richmond
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	23219
City Area Code	(650)
Local Phone Number	870-1200
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash	$ 2,115,206	$ 7,872,061
Accounts receivable	248,777	89,844
Prepaid expenses	534,943	460,102
Note receivable	500,000	500,000
Inventory	1,041,955	494,697
TOTAL CURRENT ASSETS	4,440,881	9,416,704
Fixed assets, net	2,318,247	2,267,297
Intangible assets, net	187,250	214,000
ROU asset - long term	3,883,781	4,097,117
Deposits	446,837	379,250
Other assets	515,104	289,539
TOTAL ASSETS	11,792,100	16,663,907
CURRENT LIABILITIES:
Accounts payable and accrued expenses	2,559,122	1,575,543
Financing on fixed assets – current	626,290	700,433
Deferred rent	191,118	186,058
Lease liability - current	1,137,980	1,145,126
TOTAL CURRENT LIABILITIES	4,514,510	3,607,160
Financing on fixed assets - long term		110,041
Lease liability - long term	2,554,683	2,765,933
TOTAL LIABILITIES	7,069,193	6,483,134
STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par value, 3,000,000 shares authorized, zero shares issued and outstanding, respectively
Common stock, $0.001 par value, 100,000,000 shares authorized, 44,826,641 and 44,530,486 shares issued and 44,725,838 and 44,429,683 shares outstanding, respectively	44,830	44,534
Treasury stock, 100,803 and 100,803 shares, respectively	(201,605)	(201,605)
Additional paid-in capital	78,291,632	77,690,653
Accumulated deficit	(73,411,950)	(67,352,809)
TOTAL STOCKHOLDERS’ EQUITY	4,722,907	10,180,773
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 11,792,100	$ 16,663,907

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	44,826,641	44,530,486
Common stock, shares outstanding	44,725,838	44,429,683
Treasury stock	100,803	100,803

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
REVENUE
Sales	$ 210,279
Cost of goods sold	188,071
Gross Profit	22,208
OPERATING EXPENSES
General and administrative expenses, including $451,987 and $1,464,902, in stock-based compensation, respectively	4,624,158	5,098,517
Research and development expenses, including $149,288, and $0 in stock-based compensation, respectively	1,428,382	935,952
Sales and marketing expenses, including $0, and $0 in stock-based compensation, respectively	86,599	58,563
Total operating expenses	6,139,139	6,093,032
NET LOSS FROM OPERATIONS	(6,116,931)	(6,093,032)
OTHER INCOME (EXPENSE)
Interest expense	(15,210)	(16,803)
Interest income	14,040	249
Other income	58,960
Amortization of debt discount		(270,081)
Total other income (expense)	57,790	(286,635)
Net loss before income taxes	(6,059,141)	(6,379,667)
Income tax provision
NET LOSS	$ (6,059,141)	$ (6,379,667)
Net loss per share - basic and diluted (in Dollars per share)	$ (0.14)	$ (0.3)
Weighted average number of shares outstanding during the period - basic and diluted (in Shares)	44,580,713	13,829,124

Condensed Statements of Opera_2

Condensed Statements of Operations (Unaudited) (Parentheticals) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
General and administrative expenses
Stock-based compensation	$ 451,987	$ 1,464,902
Research and development
Stock-based compensation	149,288	0
Sales and marketing
Stock-based compensation	$ 0	$ 0

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Shares	Common Shares	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2020		$ 13,078	$ (201,605)	$ 32,079,187	$ (20,879,178)	$ 11,011,482
Balance (in Shares) at Dec. 31, 2020		12,973,692
Exercise of warrants		$ 1,164		3,717,792		3,718,956
Exercise of warrants (in Shares)		1,163,556
Stock option and warrant compensation				301,462		301,462
Fair value of warrants issued with convertible note payable				1,322,840		1,322,840
Warrant consideration for convertible note offering costs				231,316		231,316
Issuance of shares for services		$ 18		51,222		51,240
Issuance of shares for services (in Shares)		18,000
Issuance of shares for compensation		$ 335		1,111,865		1,112,200
Issuance of shares for compensation (in Shares)		335,000
Net loss					(6,379,667)	(6,379,667)
Balance at Mar. 31, 2021		$ 14,595	(201,605)	38,815,684	(27,258,845)	11,369,829
Balance (in Shares) at Mar. 31, 2021		14,490,248
Balance at Dec. 31, 2021		$ 44,534	(201,605)	77,690,653	(67,352,809)	10,180,773
Balance (in Shares) at Dec. 31, 2021		44,429,683
Stock option and warrant compensation				219,885		219,885
Issuance of restricted stock units for compensation		$ 287		(287)
Issuance of restricted stock units for compensation (in Shares)		287,155
Restricted stock unit compensation				377,671		377,671
Issuance of shares for services		$ 9		3,710		3,719
Issuance of shares for services (in Shares)		9,000
Net loss					(6,059,141)	(6,059,141)
Balance at Mar. 31, 2022		$ 44,830	$ (201,605)	$ 78,291,632	$ (73,411,950)	$ 4,722,907
Balance (in Shares) at Mar. 31, 2022		44,725,838

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,059,141)	$ (6,379,667)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation	601,275	1,464,902
Depreciation expense	96,852	66,243
Amortization of intangible assets	26,750	26,384
Amortization of debt discount		270,081
Changes in operating assets and liabilities:
Prepaid expenses	(74,841)	(233,011)
Deposits	(67,587)
Accounts payable and accrued expenses	983,579	731,339
Accounts receivable	(158,933)
Inventory	(547,258)
Net cash used in operating activities	(5,199,304)	(4,053,729)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(147,802)	(486,450)
Tenant improvement allowance receivable	(211,661)
Notes receivable and accrued interest	(13,904)
Net cash used in investing activities	(373,367)	(486,450)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible note payable		5,000,000
Discount on convertible note payable from offering costs		(526,460)
Proceeds from exercise of warrants		3,718,956
Payments on financing on fixed asset	(184,184)	(108,107)
Net cash (used in) provided by financing activities	(184,184)	8,084,389
NET (DECREASE) INCREASE IN CASH	(5,756,855)	3,544,210
CASH AT BEGINNING OF PERIOD	7,842,061	10,500,826
CASH AT END OF PERIOD	2,115,206	14,045,036
Supplemental cash flow information:
Cash paid for income taxes
Cash paid for interest expense
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Original offering discount on note payable		1,000,000
Debt discount from warrants issued with convertible note payable		1,322,840
Debt discount from warrant consideration for convertible debt offering costs		231,316
Liability recognized for financed assets		$ 821,862

Organization and Nature of Busi

Organization and Nature of Business	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND NATURE OF BUSINESS	NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Company Background Overview Aditxt, Inc. (“Aditxt” or the “Company”), formerly known as Aditx Therapeutics, Inc., was incorporated in the State of Delaware on September 28, 2017, and the Company’s headquarters are located in Richmond, VA. The Company is a biotech innovation company with a mission of prolonging life and enhancing its quality by improving the health of the immune system. The Company is developing biotechnologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. The Company’s immune reprogramming technologies are currently at the pre-clinical stage and are designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. The Company’s immune monitoring technologies are designed to provide a personalized comprehensive profile of the immune system, and the Company plans to utilize them in its upcoming reprogramming clinical trials to monitor subjects’ immune response before, during and after drug administration. Offerings On August 31, 2021, the Company completed a registered direct offering (“August 2021 Offering”). In connection therewith, the Company issued 4,583,334 shares of common stock, at a purchase price of $2.40 per share, resulting in gross proceeds of approximately $11.0 million. In a concurrent private placement, the Company issued warrants to purchase up to 4,583,334 shares. The warrants have an exercise price of $2.53 per share and are exercisable for a five-year period commencing six months from the date of issuance. The warrants exercise price was subsequently repriced to $1.50. In addition, the Company issued a warrant to the placement agent to purchase up to 229,166 shares of common stock at an exercise price of $3.00 per share. On October 18, 2021, the Company entered into an underwriting agreement with Revere Securities LLC, relating to the public offering (the “October 2021 Offering”) of 2,833,333 shares of the Company’s common stock (the “Shares”) by the Company. The Shares were offered, issued, and sold at a price to the public of $1.50 per share under a prospectus supplement and accompanying prospectus filed with the SEC pursuant to an effective shelf registration statement filed with the SEC on Form S-3 (File No. 333-257645), which was declared effective by the SEC on July 13, 2021. The October 2021 Offering closed on October 20, 2021 for gross proceeds of $4.25 million. The Company utilized a portion of the proceeds, net of underwriting discounts of approximately $3.91 million from the October 2021Offering to fund certain obligations under the Credit Agreement. (See Note 4) On December 6, 2021, we completed an offering for net proceeds of $16.0 million. As part of this offering, we issued 8,246,430 units consisting of shares of the Company’s common stock and warrant to purchase shares of the Company’s common stock and 8,328,570 prefunded warrants. The warrant issued as part of the units had an exercise price of $1.15 and the prefunded warrants had an exercise price of $0.001. Risks and Uncertainties The Company has a limited operating history and is in the very early stages of generating revenue from intended operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include: changes in the biotechnology regulatory environment, technological advances that render our technologies obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies. These adverse conditions could affect the Company’s financial condition and the results of its operations. On January 30, 2020, the World Health Organization declared the COVID-19 novel coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the financial impact will be to the Company, it is reasonably possible that future capital raising efforts and additional development of our technologies may be negatively affected.

Going Concern Analysis

Going Concern Analysis	3 Months Ended
	Mar. 31, 2022
Going Concerns Disclosure [Abstract]
GOING CONCERN ANALYSIS	NOTE 2 – GOING CONCERN ANALYSIS Management Plans The Company was incorporated on September 28, 2017 and has not generated significant revenues to date. During the three months ended March 31, 2022, the Company had a net loss of $6,059,141 and negative cash flow from operating activities of $5,199,304. As of March 31, 2022 the Company’s cash balance was $2,115,206. The Company has $67.3 million of remaining availability, subject to regulatory requirements, to raise future funds pursuant to an effective shelf registration statement filed with the SEC on Form S-3 declared effective on July 13, 2021. However, factors such as stock price, volatility, trading volume, market conditions, demand and regulatory requirements may adversely affect the Company’s ability to raise capital in an efficient manner. Because of these factors, the Company believes that this creates substantial doubt with the Company’s ability to continue as a going concern. The condensed financial statements included in this report do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein. The Company’s ability to continue as a going concern is dependent upon the ability to complete clinical studies and implement the business plan, generate sufficient revenues and to control operating expenses. In addition, the Company is consistently focused on raising capital, strategic acquisitions and alliances, and other initiatives to strengthen the Company.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, the accompanying condensed financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended March 31, 2022 and March 31, 2021. Although management believes that the disclosures in these unaudited condensed financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in condensed financial statements that have been prepared in accordance U.S. GAAP have been omitted pursuant to the rules and regulations of the SEC. The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s financial statements and notes related thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022. The interim results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ended December 31, 2022 or for any future interim periods. Use of Estimates The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed financial statements include the fair value of stock options and warrants. Fair Value Measurements and Fair Value of Financial Instruments The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3 - Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates. Concentrations of Credit Risk The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. Cash and Cash Equivalents Cash and cash equivalents include short-term, liquid investments. Inventory Inventory consists of laboratory materials and supplies used in laboratory analysis. We capitalize inventory when purchased. Inventory is valued at the lower of cost or net realizable value on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable. Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and other assets. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The costs of fixed assets are depreciated using the straight-line method over the estimated useful lives or lease life of the related assets. Intangible Assets Intangible assets are stated at cost less accumulated amortization. For intangible assets that have finite lives, the assets are amortized using the straight-line method over the estimated useful lives of the related assets. For intangible assets with indefinite lives, the assets are tested periodically for impairment. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are stated at the amount management expects to collect from outstanding balances. The Company generally does not require collateral to support customer receivables. The Company determines if receivables are past due based on days outstanding, and amounts are written off when determined to be uncollectible by management. As of March 31, 2022 and 2021, there was no allowance for doubtful accounts deemed necessary. Revenue Recognition In accordance with ASC 606 (Revenue From Contracts with Customers), revenue is recognized when a customer obtains control of promised services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps: 1) Identify the contract with a customer 2) Identify the performance obligations in the contract 3) Determine the transaction price 4) Allocate the transaction price to performance obligations in the contract 5) Recognize revenue when or as the Company satisfies a performance obligation Revenues reported from services provided by the AditxtScore™ division are recognized when the AditxtScore™ report is delivered to the customer. The services performed include the analysis of specimens received in Aditxt’s CLIA laboratory and the generation of results which are then delivered upon completion. Fees per test in the client payer channel are determined based on contractual arrangements with our customers. Generally, client revenues are recorded based on the number of AditxtScore™ reports delivered at the contractual rate per test. Leases Under Topic 842 (Leases), operating lease expense is generally recognized evenly over the term of the lease. The Company has operating leases consisting of office space, laboratory space, and lab equipment. Leases with an initial term of twelve months or less are not recorded on the balance sheet. We combine the lease and non-lease components in determining the lease liabilities and right of use (“ROU”) assets. Stock-Based Compensation The Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock-based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation is recognized as expense over the employee’s requisite vesting period and over the nonemployee’s period of providing goods or services. Patents The Company incurs fees from patent licenses, which are expensed as incurred. During the three months ended March 31, 2022 and March 31, 2021, the Company incurred patent licensing fees for the patents of $225,013 and $69,360, respectively. Research and Development We incur research and development costs during the process of researching and developing our technologies and future offerings. We expense these costs as incurred unless such costs qualify for capitalization under applicable guidance. During the three months ended March 31, 2022 and March 31, 2021, the Company incurred research and development costs of $1,428,382 and $935,952, respectively. Basic and Diluted Net Loss per Common Share Basic loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As of March 31, 2022, 2,235,466 stock options, 1,028,650 unvested restricted stock units, and 30,012,614 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. As of March 31, 2021, 2,143,000 stock options and 5,463,715 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. Recent Accounting Pronouncements The FASB issues ASUs to amend the authoritative literature in ASC. There have been several ASUs to date, including those above, that amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact on our condensed financial statements.

Note Receivable

Note Receivable	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
NOTE RECEIVABLE	NOTE 4 – NOTE RECEIVABLE Cellvera Global Note Receivable On August 25, 2021, the Company entered into a letter of intent (“the LOI”) to acquire AiPharma Global Holdings LLC, a Delaware limited liability company, which changed its name to Cellvera Global Holdings LLC (“Cellvera Global”) which is commercializing COVID-19 antiviral oral therapy. Key terms of the proposed transaction as stated in the Letter of Intent included: the completion of a proposed $6.5 million secured loan from the Company to Cellvera Global by August 31, 2021, as well as the issuance of such number of shares of the Company’s common stock that yields 50% of the number of the Company’s outstanding shares post-closing of the transaction. The acquisition is subject to the satisfaction of numerous conditions, including satisfactory due diligence, the negotiation and execution of definitive agreements and other closing conditions, including board and shareholder approval and approval by Nasdaq of the listing of shares proposed to be issued in the transaction. The Company and Cellvera Global agreed to an exclusivity period until September 30, 2021 (the “Exclusivity Period”), with a view to settling the definitive agreement. On September 30, 2021, the parties entered into a letter agreement pursuant to which they agreed to extend the Exclusivity Period until October 4, 2021. On December 28, 2021, we entered into a Share Exchange Agreement with Cellvera Global f/k/a AiPharma Global, pursuant to which we (i) will acquire 9.5% of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 4,816,193 shares of our common stock of Aditxt and a cash payment of $250,000, at an initial closing upon the satisfaction or waiver of certain conditions to closing; and (ii) acquire the remaining 90.5% of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 39,927,974 shares of our common stock and a cash payment of $250,000 at a secondary closing upon the satisfaction or waiver of certain conditions to closing. Additionally, we may elect to raise additional capital due to market conditions or strategic considerations. In connection with the contemplated acquisition with Cellvera Global, the Company entered into a secured credit agreement dated August 27, 2021 (the “Credit Agreement”) with Cellvera Global and certain affiliated entities (collectively, the “Borrower”), pursuant to which the Company made a secured loan to Cellvera Global in the principal amount of $6.5 million (the “Loan”). The Loan was funded on August 31, 2021, following the closing of the Company’s August 2021 Offering. The Loan bears interest at a rate of 8% per annum and matured on November 30, 2021. The Loan is secured by certain accounts receivable and other assets of Cellvera Global and certain of its affiliates. The Credit Agreement also contains certain covenants that prohibit Cellvera Global from incurring additional indebtedness, incurring liens or making any dispositions of its property. On October 18, 2021, the Company entered into the first amendment to the Credit Agreement with Cellvera Global and certain affiliated entities (the “Credit Agreement Amendment”), pursuant to which the Company agreed to increase the amount which Cellvera Global was permitted to borrow under the Credit Agreement by $8.5 million to an aggregate of $15.0 million, of which $6.5 million was outstanding prior to entering the Credit Agreement Amendment. The Company agreed to fund such additional borrowings, as requested by Cellvera Global, by advancing 70% of any amounts received by the Company from the exercise of existing warrants or any other capital raises, including the October Offering. As of December 31, 2021 an additional $8.0 million was advanced under the Credit Agreement for a total of $14.5 million. The Credit Agreement was amended on multiple occasions, for which the final amendment was signed on December 31, 2021, extending the Loan’s maturity date to January 31, 2022. The Company determined that Cellvera Global may not have the ability to repay the note receivable. Accordingly, the Company recognized a full impairment of $14.5 million as of December 31, 2021. Forbearance Agreement: On January 31, 2022, the Company’s $14.5 million loan to Cellvera Global became fully due and payable under the Credit Agreement. On February 14, 2022, the Company entered into a Forbearance Agreement and Seventh Amendment to Credit Agreement (the “Forbearance Agreement”) with Cellvera Global. Pursuant to the Forbearance Agreement, the Company agreed to forbear from exercising its rights and remedies against Cellvera Global and certain affiliated guarantor parties until the earlier of (i) June 30, 2022 or (ii) the date of occurrence of any event of default under the Forbearance Agreement (the “Forbearance Period”). Given that the parties continue to conduct due diligence in connection with the Share Exchange Agreement the Company and Cellvera Global also agreed that should the initial closing occur under the Share Exchange Agreement, the existing event of default will be waived. Under the Forbearance Agreement, the Company and Cellvera Global also agreed to certain amendments to the Credit Agreement, including, but not limited to: (i) the delivery by the Borrower of certain financial statements and forecasts, and (ii) certain regularly scheduled payments to be made by Cellvera Global to the Company during the Forbearance Period. As of the date these financial statements were available to be issued; the regularly scheduled payments under the Forbearance Agreement were not made, and the note receivable remains fully impaired. Target Company Note Receivable On December 10, 2021, the Company entered into a secured credit agreement dated December 10, 2021 (the “Target Company Credit Agreement”) and signed on December 10, 2021 with the Target Company, pursuant to which the Company made a secured loan to the Target Company in the principal amount of $500,000 (the “Target Company Loan”) and agreed to make additional secured loans, as requested by the Target Company and approved by the Company, in an amount not to exceed $4.5 million. The Target Company Loan bears interest at a rate of 8% per annum and mature on December 8, 2022, provided, that the Letter of Intent currently contemplates that the Target Company Loan will be forgivable upon the closing of the acquisition contemplated by the letter of intent. The Target Company Credit Agreement also contains certain covenants that prohibit the Target Company from incurring additional indebtedness, entering into any fundamental transactions, issuing any equity interests subject to certain limited exceptions, or making any dispositions of its property. In connection with the Target Company Credit Agreement, the Company entered into a Security Agreement with the Target Company, pursuant to which the Target Company granted the Company a security interest in all of the Target Company’s assets as security for the Target Company Loan. As of March 31, 2022, the outstanding principal of the Target Company Loan is $500,000 and the accrued interest on the Loan is $16,425.

Fixed Assets

Fixed Assets	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
FIXED ASSETS	NOTE 5 – FIXED ASSETS The Company’s fixed assets include the following on March 31, 2022: Cost Basis Accumulated Net Computers $ 370,607 $ (105,150 ) $ 265,457 Lab Equipment 2,366,240 (374,182 ) 1,992,058 Office Furniture 56,656 (3,951 ) 52,705 Other Fixed Assets 8,605 (578 ) 8,027 Total Fixed Assets $ 2,802,108 $ (483,861 ) $ 2,318,247 The Company’s fixed assets include the following on December 31, 2021: Cost Basis Accumulated Net Computers $ 312,489 $ (75,053 ) $ 237,436 Lab Equipment 2,240,252 (306,688 ) 1,933,564 Office Furniture 90,757 (4,857 ) 85,900 Other Fixed Assets 10,809 (412 ) 10,397 Total Fixed Assets $ 2,654,307 $ (387,010 ) $ 2,267,297 Depreciation expense was $96,852 and $66,243, for the three months ended March 31, 2022 and 2021, respectively. None of the Company’s fixed assets serve as collateral against any loans as of March 31, 2022 and December 31, 2021, other than those subject to the financed asset liability.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 6 – INTANGIBLE ASSETS The Company’s intangible assets include the following on March 31, 2022: Cost Basis Accumulated Net Proprietary Technology $ 321,000 $ (133,750 ) $ 187,250 Total Intangible Assets $ 321,000 $ (133,750 ) $ 187,250 The Company’s intangible assets include the following on December 31, 2021: Cost Basis Accumulated Net Proprietary Technology $ 321,000 $ (107,000 ) $ 214,000 Total Intangible Assets $ 321,000 $ (107,000 ) $ 214,000 Amortization expense was $26,750 and $26,384 for the three months ended March 31, 2022 and 2021, respectively. None of the Company’s intangible assets serve as collateral against any loans as of March 31, 2022, and December 31, 2021.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 7 – RELATED PARTY TRANSACTIONS On January 26, 2022, the Company granted 480,000 restricted stock units to an officer of the Company pursuant to the Company’s 2021 Equity Incentive Plan. The Company recognized $87,420 in stock-based compensation for the issuance of these vested and unvested restricted stock units during the period ended March 31, 2022. (Note 9)

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
LEASES	NOTE 8 – LEASES Our lease agreements generally do not provide an implicit borrowing rate; therefore, an internal incremental borrowing rate is determined based on information available at lease commencement date for purposes of determining the present value of lease payments. We used the incremental borrowing rate on March 31, 2022 and December 31, 2021 for all leases that commenced prior to that date. In determining this rate, which is used to determine the present value of future lease payments, we estimate the rate of interest we would pay on a collateralized basis, with similar payment terms as the lease and in a similar economic environment. Lease Costs Three Months Three Months Components of total lease costs: Operating lease expense $ 322,495 $ 124,614 Total lease costs $ 322,495 $ 124,614 Lease Positions as of March 31, 2022 and December 31, 2021 ROU lease assets and lease liabilities for our operating leases are recorded on the balance sheet as follows: March 31, December 31, Assets Right of use asset – long term $ 3,883,781 $ 4,097,117 Total right of use asset $ 3,883,781 $ 4,097,117 Liabilities Operating lease liabilities – short term $ 1,137,980 $ 1,145,126 Operating lease liabilities – long term 2,554,683 2,765,933 Total lease liability $ 3,692,663 $ 3,911,059 Lease Terms and Discount Rate Weighted average remaining lease term (in years) – operating leases 2.30 Weighted average discount rate – operating leases 8.00 %

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 9 – STOCKHOLDERS’ EQUITY Common Stock On May 24, 2021, the Company increased the number of authorized shares of the Company’s common stock, par value $0.001 per share, from 27,000,000 to 100,000,000 (the “Authorized Shares Increase”) by filing a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware. In accordance with the General Corporation Law of the State of Delaware, the Authorized Shares Increase and the Certificate of Amendment were approved by the stockholders of the Company at the Company’s Annual Meeting of Stockholders on May 19, 2021. During the three months ended March 31, 2022, the Company issued 9,000 shares of common stock and recognized expense of $3,719 in stock-based compensation for consulting services. The Company also granted 582,200 Restricted Stock Units, of which 287,850 vested and resulted in the issuance of shares. As a result, the Company recognized expense of $377,671 in stock-based compensation. The stock-based compensation for shares issued or RSU’s granted during the period were valued based on the fair market value on the date of grant. During the three months ended March 31, 2021, the Company issued 18,000 shares of common stock and recognized expense of $51,240 in stock-based compensation for consulting services. The Company also issued 1,163,556 shares of common stock for the exercise of warrants and received $3,718,956 in cash proceeds. The Company granted 335,000 shares of restricted common stock for compensation and recognized expense of $1,112,200 in stock-based compensation. The stock-based compensation for the period was valued based on the value of the shares based on public information. Preferred Stock The Company is authorized to issue 3,000,000 shares of preferred stock, par value $0.001 per share. There were no shares of preferred stock outstanding as of March 31, 2022 and December 31, 2021, respectively. Stock-Based Compensation In October 2017, our Board of Directors adopted the Aditx Therapeutics, Inc. 2017 Equity Incentive Plan (the “2017 Plan”). The 2017 Plan provides for the grant of equity awards to directors, employees, and consultants. The Company is authorized to issue up to 2,500,000 shares of our common stock pursuant to awards granted under the 2017 Plan. The 2017 Plan is administered by our Board of Directors, and expires ten years after adoption, unless terminated earlier by the Board of Directors. On February 24, 2021, our Board of Directors adopted the Aditx Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “2021 Plan”). The 2021 Plan provides for grants of nonqualified stock options, incentive stock options, stock appreciation rights, restricted stock and restricted stock units, and other stock-based awards (collectively, the “Awards”). Eligible recipients of Awards include employees, directors or independent contractors of the Company or any affiliate of the Company. The Compensation Committee of the Board of Directors (the “Committee”) will administer the 2021 Plan. A total of 3,000,000 shares of common stock, par value $0.001 per share, of the Company may be issued pursuant to Awards granted under the 2021 Plan. The exercise price per share for the shares to be issued pursuant to an exercise of a stock option will be no less than one hundred percent (100%) of the Fair Market Value (as defined in the 2021 Plan) of a share of Common Stock on the date of grant. The 2021 Plan was submitted and approved by the Company’s stockholders at the 2021 annual meeting of stockholders, held on May 19, 2021. During the three months ended March 31, 2022 and 2021, the Company granted no new options. The following is an analysis of the stock option grant activity under the Plan: Vested and Nonvested Stock Options Number Weighted Weighted Outstanding December 31, 2021 2,235,466 $ 3.40 6.74 Granted - - - Exercised - - - Expired or forfeited - - - Outstanding March 31, 2022 2,235,466 $ 3.40 6.50 Nonvested Stock Options Number Weighted- Nonvested on December 31, 2020 453,125 $ 2.17 Granted - - Vested (116,875 ) 2.17 Forfeited - - Nonvested on March 31, 2022 336,250 $ 2.18 The Company recognized stock-based compensation expense related to options granted and vesting expense of $193,624 during the three months ended March 31, 2022, of which $133,660 is included in general and administrative expenses and $59,964 is included in research and development expenses in the accompanying statements of operations. The remaining value to be expensed is $777,456 with a weighted average vesting term of 0.62 years as of March 31, 2022. The Company recognized stock-based compensation expense related to options issued and vesting of $211,579 during the three months ended March 31, 2021, which is included in general and administrative expenses in the accompanying statements of operations. Warrants During the three months ended March 31, 2022 the Company granted no new warrants. During the three months ended March 31, 2021, the Company granted 875,000 warrants. For the three months ended March 31, 2022 there were no new warrants granted, therefore no fair value was assigned. For the three months ended March 31, 2021, the fair value of each warrant granted was estimated using the assumption ranges and/or factors in the Black-Scholes Model as follows: Exercise price $ 4.00 Expected dividend yield 0 % Risk free interest rate 0.17%-0.42 % Expected life in years 3.00-5.00 Expected volatility 154%-159 % The risk-free interest rate assumption for warrants granted is based upon observed interest rates on the United States Government Bond Equivalent Yield appropriate for the expected term of warrants. The Company determined the expected volatility assumption for warrants granted using the historical volatility of comparable public companies’ common stock. The Company will continue to monitor peer companies and other relevant factors used to measure expected volatility for future warrant grants, until such time that the Company’s common stock has enough market history to use historical volatility. The dividend yield assumption for warrants granted is based on the Company’s history and expectation of dividend payouts. The Company has never declared nor paid any cash dividends on its common stock, and the Company does not anticipate paying any cash dividends in the foreseeable future. The Company recognizes warrant forfeitures as they occur as there is insufficient historical data to accurately determine future forfeitures rates. A summary of warrant issuances are as follows: Vested and Nonvested Warrants Number Weighted Weighted Outstanding December 31, 2021 30,069,964 $ 1.67 4.38 Granted - - - Exercised - - - Expired or forfeited (57,350 ) 5.79 - Outstanding March 31, 2022 30,012,614 $ 1.66 4.27 Nonvested Warrants Number Weighted- Nonvested on December 31, 2021 4,628,334 $ 1.51 Granted - - Vested (4,598,334 ) 1.50 Forfeited - Nonvested on March 31, 2022 30,000 $ 1.92 The Company recognized stock-based compensation expense related to warrants granted and vesting expense of $26,262 and $89,883 during the three months ended March 31, 2022 and March 31, 2021, respectively, which is included in general and administrative in the accompanying Statements of Operations. The remaining value to be expensed is $78,787 with a weighted average vesting term of 0.50 years as of March 31, 2022. Restricted Stock Units A summary of Restricted Stock Units (“RSUs”) issuances are as follows: Nonvested RSUs Number Weighted Nonvested December 31, 2021 778,250 $ 1.92 Granted 582,200 0.45 Vested (287,850 ) 1.00 Forfeited (43,950 ) 2.00 Nonvested March 31, 2022 1,028,650 $ 1.35 The Company recognized stock-based compensation expense related to RSUs granted and vesting expense of $377,671 and zero during the three months ended March 31, 2022 and March 31, 2021, respectively, of which, $288,346 is included in general and administrative and $89,325 is included in research and development in the accompanying Statements of Operations. The remaining value to be expensed is $1,197,321 with a weighted average vesting term of 0.97 years as of March 31, 2022. During the three months ended March 31, 2022, the Company granted a total of 582,200 RSUs. As of March 31, 2022, 287,850 of these RSUs vested and the Company issued 287,850 shares of common stock for the 287,850 vested RSUs.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 10 – INCOME TAXES The Company has incurred losses since inception. During the nine months ended March 31, 2022, the Company did not provide any provision for income taxes as the Company incurred losses during such period. The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “Accounting for Income Taxes”. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities and for operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. In assessing the need for a valuation allowance, the Company has considered both positive and negative evidence related to the likelihood of realization of deferred tax assets using a “more likely than not” standard. In making such assessment, more weight was given to evidence that could be objectively verified, including recent cumulative losses. Based on the Company’s review of this evidence, the Company has recorded a full valuation allowance for its net deferred tax assets as of March 31, 2022. As of March 31, 2022, the Company did not have any amounts recorded pertaining to uncertain tax positions.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 – SUBSEQUENT EVENTS Cellvera Global: On April 4, 2022, the Company and Cellvera Global entered into a Forbearance Agreement and Eighth Amendment to the Credit Agreement (the “April Forbearance Agreement”) pursuant to which among other things (i) the Company agreed to extend the forbearance period until the earlier of March 31, 2023 or the date of occurrence of any event of default under the April Forbearance Agreement, (ii) Cellvera Global shall be permitted to factor certain receivables, and (iii) certain conforming changes were made relating to the Revenue Sharing Agreement (as defined below). In connection with the Forbearance Agreement, the Company entered into a series of security agreements with Cellvera Global (the “Security Agreements”) and certain affiliated entities pursuant to which Cellvera Global enhanced the Company’s security interest in connection with the Credit Agreement. In addition, and as a condition to entering into the April Forbearance Agreement, the Company required that Cellvera Global enter into a Revenue Sharing Agreement (the “Revenue Sharing Agreement”), pursuant to which, among other things, Cellvera Global agreed to pay the Company a certain portion of its revenues up to the aggregate amount of $30 million. Concurrently with the execution of the April Forbearance Agreement and the Revenue Sharing Agreement, the Company and AiPharma Group, Ltd. entered into an Amendment to the Share Exchange Agreement (the “Share Exchange Amendment”) which amended the Share Exchange Agreement to, among other things: (i) modify the financial statements required to be delivered by AiPharma Group, Ltd. at the initial closing to include the unaudited financial statements for the three months ended March 31, 2022 and 2021, (ii) permit the Company to amend its Certificate of Incorporation without the consent of AiPharma Group, Ltd. in order to effect a reverse stock split of the Company’s common stock, if necessary, in order to maintain its listing on the Nasdaq Capital Market, and (iii) make certain other conforming changes related to the March Forbearance Agreement and Revenue Sharing Agreement. Common stock offering: On May 14, 2022, the Company entered into a securities purchase agreement (the “May 2022 Purchase Agreement”) with an accredited investor, pursuant to which the Company agreed to issue and sell an aggregate of 8,333,334 shares of the Company’s common stock (the “Shares”) at a per share purchase price of $0.30 for gross proceeds to the Company of $2.5 million. For each Share purchased, the investor also received a warrant to purchase one share of the Company’s common stock (the “Warrants”). The Warrants have an exercise price of $0.33 per share and are exercisable for a term of five years commencing six months from the date of closing. Pursuant to the May 2022 Purchase Agreement, the Company agreed to file a registration statement registering the Shares and the shares of common stock underlying the Warrants within sixty days after the closing. The closing is expected to occur on or about May 20, 2022.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, the accompanying condensed financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended March 31, 2022 and March 31, 2021. Although management believes that the disclosures in these unaudited condensed financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in condensed financial statements that have been prepared in accordance U.S. GAAP have been omitted pursuant to the rules and regulations of the SEC. The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s financial statements and notes related thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022. The interim results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ended December 31, 2022 or for any future interim periods.
Use of Estimates	Use of Estimates The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed financial statements include the fair value of stock options and warrants.
Fair Value Measurements and Fair Value of Financial Instruments	Fair Value Measurements and Fair Value of Financial Instruments The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3 - Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include short-term, liquid investments.
Inventory	Inventory Inventory consists of laboratory materials and supplies used in laboratory analysis. We capitalize inventory when purchased. Inventory is valued at the lower of cost or net realizable value on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.
Fixed Assets	Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and other assets. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The costs of fixed assets are depreciated using the straight-line method over the estimated useful lives or lease life of the related assets.
Intangible Assets	Intangible Assets Intangible assets are stated at cost less accumulated amortization. For intangible assets that have finite lives, the assets are amortized using the straight-line method over the estimated useful lives of the related assets. For intangible assets with indefinite lives, the assets are tested periodically for impairment.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are stated at the amount management expects to collect from outstanding balances. The Company generally does not require collateral to support customer receivables. The Company determines if receivables are past due based on days outstanding, and amounts are written off when determined to be uncollectible by management. As of March 31, 2022 and 2021, there was no allowance for doubtful accounts deemed necessary.
Revenue Recognition	Revenue Recognition In accordance with ASC 606 (Revenue From Contracts with Customers), revenue is recognized when a customer obtains control of promised services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps: 1) Identify the contract with a customer 2) Identify the performance obligations in the contract 3) Determine the transaction price 4) Allocate the transaction price to performance obligations in the contract 5) Recognize revenue when or as the Company satisfies a performance obligation Revenues reported from services provided by the AditxtScore™ division are recognized when the AditxtScore™ report is delivered to the customer. The services performed include the analysis of specimens received in Aditxt’s CLIA laboratory and the generation of results which are then delivered upon completion.
Leases	Leases Under Topic 842 (Leases), operating lease expense is generally recognized evenly over the term of the lease. The Company has operating leases consisting of office space, laboratory space, and lab equipment. Leases with an initial term of twelve months or less are not recorded on the balance sheet. We combine the lease and non-lease components in determining the lease liabilities and right of use (“ROU”) assets.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock-based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation is recognized as expense over the employee’s requisite vesting period and over the nonemployee’s period of providing goods or services.
Patents	Patents The Company incurs fees from patent licenses, which are expensed as incurred. During the three months ended March 31, 2022 and March 31, 2021, the Company incurred patent licensing fees for the patents of $225,013 and $69,360, respectively.
Research and Development	Research and Development We incur research and development costs during the process of researching and developing our technologies and future offerings. We expense these costs as incurred unless such costs qualify for capitalization under applicable guidance. During the three months ended March 31, 2022 and March 31, 2021, the Company incurred research and development costs of $1,428,382 and $935,952, respectively.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share Basic loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As of March 31, 2022, 2,235,466 stock options, 1,028,650 unvested restricted stock units, and 30,012,614 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. As of March 31, 2021, 2,143,000 stock options and 5,463,715 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The FASB issues ASUs to amend the authoritative literature in ASC. There have been several ASUs to date, including those above, that amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact on our condensed financial statements.

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of fixed assets	Cost Basis Accumulated Net Computers $ 370,607 $ (105,150 ) $ 265,457 Lab Equipment 2,366,240 (374,182 ) 1,992,058 Office Furniture 56,656 (3,951 ) 52,705 Other Fixed Assets 8,605 (578 ) 8,027 Total Fixed Assets $ 2,802,108 $ (483,861 ) $ 2,318,247 Cost Basis Accumulated Net Computers $ 312,489 $ (75,053 ) $ 237,436 Lab Equipment 2,240,252 (306,688 ) 1,933,564 Office Furniture 90,757 (4,857 ) 85,900 Other Fixed Assets 10,809 (412 ) 10,397 Total Fixed Assets $ 2,654,307 $ (387,010 ) $ 2,267,297

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Cost Basis Accumulated Net Proprietary Technology $ 321,000 $ (133,750 ) $ 187,250 Total Intangible Assets $ 321,000 $ (133,750 ) $ 187,250 Cost Basis Accumulated Net Proprietary Technology $ 321,000 $ (107,000 ) $ 214,000 Total Intangible Assets $ 321,000 $ (107,000 ) $ 214,000

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure Text Block [Abstract]
Schedule of lease costs	Three Months Three Months Components of total lease costs: Operating lease expense $ 322,495 $ 124,614 Total lease costs $ 322,495 $ 124,614
Schedule of ROU lease assets and lease liabilities for our operating leases	March 31, December 31, Assets Right of use asset – long term $ 3,883,781 $ 4,097,117 Total right of use asset $ 3,883,781 $ 4,097,117 Liabilities Operating lease liabilities – short term $ 1,137,980 $ 1,145,126 Operating lease liabilities – long term 2,554,683 2,765,933 Total lease liability $ 3,692,663 $ 3,911,059
Schedule of lease terms and discount rate	Weighted average remaining lease term (in years) – operating leases 2.30 Weighted average discount rate – operating leases 8.00 %

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Schedule of analysis of the stock option grant activity under the plan	Vested and Nonvested Stock Options Number Weighted Weighted Outstanding December 31, 2021 2,235,466 $ 3.40 6.74 Granted - - - Exercised - - - Expired or forfeited - - - Outstanding March 31, 2022 2,235,466 $ 3.40 6.50 Vested and Nonvested Warrants Number Weighted Weighted Outstanding December 31, 2021 30,069,964 $ 1.67 4.38 Granted - - - Exercised - - - Expired or forfeited (57,350 ) 5.79 - Outstanding March 31, 2022 30,012,614 $ 1.66 4.27 Nonvested RSUs Number Weighted Nonvested December 31, 2021 778,250 $ 1.92 Granted 582,200 0.45 Vested (287,850 ) 1.00 Forfeited (43,950 ) 2.00 Nonvested March 31, 2022 1,028,650 $ 1.35
Schedule of fair value of each warrant granted	Nonvested Stock Options Number Weighted- Nonvested on December 31, 2020 453,125 $ 2.17 Granted - - Vested (116,875 ) 2.17 Forfeited - - Nonvested on March 31, 2022 336,250 $ 2.18 Nonvested Warrants Number Weighted- Nonvested on December 31, 2021 4,628,334 $ 1.51 Granted - - Vested (4,598,334 ) 1.50 Forfeited - Nonvested on March 31, 2022 30,000 $ 1.92
Schedule of fair value of each warrant granted	Exercise price $ 4.00 Expected dividend yield 0 % Risk free interest rate 0.17%-0.42 % Expected life in years 3.00-5.00 Expected volatility 154%-159 %

Organization and Nature of Bu_2

Organization and Nature of Business (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 06, 2021	Oct. 20, 2021	Oct. 18, 2021	Aug. 31, 2021	Aug. 31, 2021
Organization and Nature of Business (Details) [Line Items]
Company issued	8,246,430		2,833,333	4,583,334	4,583,334
Purchase price per share (in Dollars per share)					$ 2.4
Gross proceeds (in Dollars)		$ 4,250			$ 11,000
Issued warrants to purchase of shares					4,583,334
Debt instrument term, description					The warrants have an exercise price of $2.53 per share and are exercisable for a five-year period commencing six months from the date of issuance.
Warrant exercise price (in Dollars per share)					$ 2.53
Warrants exercise price (in Dollars per share)				$ 1.5	$ 1.5
Purchase of common stock				229,166	229,166
Exercise price per share (in Dollars per share)	$ 1.15		$ 1.5	$ 3
Net of underwriting discounts (in Dollars)		$ 3,910
Net proceeds (in Dollars)	$ 16,000
Prefunded warrants shares	8,328,570
Warrant [Member]
Organization and Nature of Business (Details) [Line Items]
Prefunded warrants shares	0.001

Going Concern Analysis (Details

Going Concern Analysis (Details)	3 Months Ended
	Mar. 31, 2022USD ($)
Going Concerns Disclosure [Abstract]
Net loss cash flow from operating activities	$ 6,059,141
Net Income (Loss) Available to Common Stockholders, Basic	(5,199,304)
Cash	2,115,206
Future funds	$ 67,300,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accounting Policies [Abstract]
Licensing fees (in Dollars)	$ 225,013	$ 69,360
Research and development expense (in Dollars)	$ 1,428,382	$ 935,952
Stock options issued	2,235,466	2,143,000
Restricted stock units	1,028,650
Dilutive earning shares	30,012,614	5,463,715

Note Receivable (Details)

Note Receivable (Details) - USD ($)	1 Months Ended			12 Months Ended
	Dec. 28, 2021	Oct. 18, 2021	Aug. 25, 2021	Dec. 31, 2021	Mar. 31, 2022	Jan. 31, 2022	Nov. 30, 2021	Aug. 30, 2021
Receivables [Abstract]
Completion of a proposed			$ 6,500,000
Common stock yields percentage			50.00%
Share exchange agreement description	On December 28, 2021, we entered into a Share Exchange Agreement with Cellvera Global f/k/a AiPharma Global, pursuant to which we (i) will acquire 9.5% of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 4,816,193 shares of our common stock of Aditxt and a cash payment of $250,000, at an initial closing upon the satisfaction or waiver of certain conditions to closing; and (ii) acquire the remaining 90.5% of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 39,927,974 shares of our common stock and a cash payment of $250,000 at a secondary closing upon the satisfaction or waiver of certain conditions to closing.
Principal amount								$ 6,500,000
Interest rate per annum							8.00%
Credit agreement amendment, description		the Company entered into the first amendment to the Credit Agreement with Cellvera Global and certain affiliated entities (the “Credit Agreement Amendment”), pursuant to which the Company agreed to increase the amount which Cellvera Global was permitted to borrow under the Credit Agreement by $8.5 million to an aggregate of $15.0 million, of which $6.5 million was outstanding prior to entering the Credit Agreement Amendment. The Company agreed to fund such additional borrowings, as requested by Cellvera Global, by advancing 70% of any amounts received by the Company from the exercise of existing warrants or any other capital raises, including the October Offering.
Advanced credit agreement				$ 8,000,000
Credit agreement				14,500,000
Note receivable amount				$ 14,500,000
Loan						$ 14,500,000
Credit agreement description				On December 10, 2021, the Company entered into a secured credit agreement dated December 10, 2021 (the “Target Company Credit Agreement”) and signed on December 10, 2021 with the Target Company, pursuant to which the Company made a secured loan to the Target Company in the principal amount of $500,000 (the “Target Company Loan”) and agreed to make additional secured loans, as requested by the Target Company and approved by the Company, in an amount not to exceed $4.5 million. The Target Company Loan bears interest at a rate of 8% per annum and mature on December 8, 2022, provided, that the Letter of Intent currently contemplates that the Target Company Loan will be forgivable upon the closing of the acquisition contemplated by the letter of intent. The Target Company Credit Agreement also contains certain covenants that prohibit the Target Company from incurring additional indebtedness, entering into any fundamental transactions, issuing any equity interests subject to certain limited exceptions, or making any dispositions of its property. In connection with the Target Company Credit Agreement, the Company entered into a Security Agreement with the Target Company, pursuant to which the Target Company granted the Company a security interest in all of the Target Company’s assets as security for the Target Company Loan.
Outstanding Principal loan					$ 500,000
Accured interest loan					$ 16,425

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 96,852	$ 66,243

Fixed Assets (Details) - Schedu

Fixed Assets (Details) - Schedule of fixed assets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Cost Basis	$ 2,802,108	$ 2,654,307
Accumulated Depreciation	(483,861)	(387,010)
Net	2,318,247	2,267,297
Computers [Member]
Property, Plant and Equipment [Line Items]
Cost Basis	370,607	312,489
Accumulated Depreciation	(105,150)	(75,053)
Net	265,457	237,436
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost Basis	2,366,240	2,240,252
Accumulated Depreciation	(374,182)	(306,688)
Net	1,992,058	1,933,564
Office Furniture [Member]
Property, Plant and Equipment [Line Items]
Cost Basis	56,656	90,757
Accumulated Depreciation	(3,951)	(4,857)
Net	52,705	85,900
Other Fixed Assets [Member]
Property, Plant and Equipment [Line Items]
Cost Basis	8,605	10,809
Accumulated Depreciation	(578)	(412)
Net	$ 8,027	$ 10,397

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 26,750	$ 26,384

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of intangible assets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Cost Basis [Member]
Finite-Lived Intangible Assets [Line Items]
Cost Basis	$ 321,000	$ 321,000
Accumulated Amortization [Member]
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	(133,750)	(107,000)
Net [Member]
Finite-Lived Intangible Assets [Line Items]
Net	$ 187,250	$ 214,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Aug. 05, 2021	Mar. 31, 2022
Related Party Transactions (Details) [Line Items]
Restricted stock of shares	480,000
RSUs [Member]
Related Party Transactions (Details) [Line Items]
Restricted stock issued		$ 87,420

Leases (Details) - Schedule of

Leases (Details) - Schedule of lease costs - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Schedule of lease costs [Abstract]
Operating lease expense	$ 322,495	$ 124,614
Total lease costs	$ 322,495	$ 124,614

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of ROU lease assets and lease liabilities for our operating leases - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Assets
Right of use asset – long term	$ 3,883,781	$ 4,097,117
Total right of use asset	3,883,781	4,097,117
Liabilities
Operating lease liabilities – short term	1,137,980	1,145,126
Operating lease liabilities – long term	2,554,683	2,765,933
Total lease liability	$ 3,692,663	$ 3,911,059

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of lease terms and discount rate	Mar. 31, 2022
Schedule of lease terms and discount rate [Abstract]
Weighted average remaining lease term (in years) – operating leases	2 years 3 months 18 days
Weighted average discount rate – operating leases	8.00%

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)	1 Months Ended		3 Months Ended
	Feb. 24, 2021	Oct. 31, 2017	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	May 24, 2021
Stockholders’ Equity (Details) [Line Items]
Common stock, par value (in Dollars per share)			$ 0.001		$ 0.001	$ 0.001
Common stock, shares authorized (in Shares)			100,000,000		100,000,000
Company issued shares (in Shares)			9,000	18,000
Stock base compensation for consulting services			$ 3,719	$ 51,240
Stock based compenastion			377,671	$ 1,112,200
Issue of common stock (in Shares)				1,163,556
Exercise of warrants and received				$ 3,718,956
Granted shares (in Shares)				335,000
Preferred stock, shares authorized (in Shares)			3,000,000		3,000,000
Preferred stock, par value (in Dollars per share)			$ 0.001		$ 0.001
Granted stock options (in Shares)	3,000,000
Fair market value	100.00%
Options granted and vesting expense			$ 193,624
General and administrative expenses			133,660
Research and development expense			59,964	$ 89,325
Share based payment remaining expenses			$ 777,456
Weighted average vesting term			7 months 13 days
Compensation expense related to options issued and vesting			$ 211,579
Weighted average vesting term			11 months 19 days
Vesting expense			$ 377,671	$ 0
Remaining value			1,197,321
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax			$ 582,200
2017 Equity Incentive Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Recognized expense (in Shares)		2,500,000
Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized (in Shares)			3,000,000
Warrants [Member]
Stockholders’ Equity (Details) [Line Items]
Share based payment remaining expenses			$ 78,787
Granted warrants (in Shares)				875,000
Weighted average vesting term			6 months
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Company issued shares (in Shares)			287,850
Shares vested (in Shares)			287,850
Minimum [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock, shares authorized (in Shares)						27,000,000
Minimum [Member] | Warrants [Member]
Stockholders’ Equity (Details) [Line Items]
Warrants issued and vesting expense			$ 26,262
Maximum [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock, shares authorized (in Shares)						100,000,000
Maximum [Member] | Warrants [Member]
Stockholders’ Equity (Details) [Line Items]
Warrants issued and vesting expense				$ 89,883
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock, par value (in Dollars per share)	$ 0.001
Restricted Stock Units (RSUs) [Member]
Stockholders’ Equity (Details) [Line Items]
Number of shares, granted (in Shares)			582,200
Number of shares, vested (in Shares)			287,850
General and administrative expenses				$ 288,346
Common stock, shares issued (in Shares)			287,850

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - Schedule of analysis of the stock option grant activity under the plan	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Vested and Nonvested Stock Options [Member]
Stockholders’ Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]
Number, Outstanding beginning balance | shares	2,235,466
Weighted Average Exercise Price, Outstanding beginning balance | $ / shares	$ 3.4
Weighted Average Remaining Life, Outstanding beginning balance	6 years 8 months 26 days
Number, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Remaining Life, Granted
Number, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Remaining Life, Exercised
Number, Expired or forfeited | shares
Weighted Average Exercise Price, Expired or forfeited | $ / shares
Weighted Average Remaining Life, Expired or forfeited
Number, Outstanding ending balance | shares	2,235,466
Weighted Average Exercise Price, Outstanding ending balance | $ / shares	$ 3.4
Weighted Average Remaining Life, Outstanding ending balance	6 years 6 months
Vested and Nonvested Warrants [Member]
Stockholders’ Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]
Number, Outstanding beginning balance | shares	30,069,964
Weighted Average Exercise Price, Outstanding beginning balance | $ / shares	$ 1.67
Weighted Average Remaining Life, Outstanding beginning balance	4 years 4 months 17 days
Number, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Remaining Life, Granted
Number, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Remaining Life, Exercised
Number, Expired or forfeited | shares	(57,350)
Weighted Average Exercise Price, Expired or forfeited | $ / shares	$ 5.79
Weighted Average Remaining Life, Expired or forfeited
Number, Outstanding ending balance | shares	30,012,614
Weighted Average Exercise Price, Outstanding ending balance | $ / shares	$ 1.66
Weighted Average Remaining Life, Outstanding ending balance	4 years 3 months 7 days
Nonvested RSUs [Member]
Stockholders’ Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]
Number, Outstanding beginning balance | shares	778,250
Weighted Average Exercise Price, Outstanding beginning balance | $ / shares	$ 1.92
Number, Granted | shares	582,200
Weighted Average Exercise Price, Granted | $ / shares	$ 0.45
Number, Vested | shares	(287,850)
Weighted Average Price, Vested | $ / shares	$ 1
Number, Forfeited | shares	(43,950)
Weighted Average Price, Forfeited | $ / shares	$ 2
Number, Outstanding ending balance | shares	1,028,650
Weighted Average Exercise Price, Outstanding ending balance | $ / shares	$ 1.35

Stockholders_ Equity (Details_2

Stockholders’ Equity (Details) - Schedule of nonvested option	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Nonvested Stock Options [Member]
Stockholders’ Equity (Details) - Schedule of nonvested option [Line Items]
Shares, Nonvested at beginning balance | shares	453,125
Weighted- Average Exercise Price, Outstanding beginning balance | $ / shares	$ 2.17
Shares, Granted | shares
Weighted- Average Exercise Price, Granted | $ / shares
Shares, Vested | shares	(116,875)
Weighted- Average Exercise Price, Vested | $ / shares	$ 2.17
Shares, Forfeited | shares
Weighted- Average Exercise Price, Forfeited | $ / shares
Shares, Nonvested at ending balance | shares	336,250
Weighted- Average Exercise Price, Outstanding ending balance | $ / shares	$ 2.18
Nonvested Warrants [Member]
Stockholders’ Equity (Details) - Schedule of nonvested option [Line Items]
Shares, Nonvested at beginning balance | shares	4,628,334
Weighted- Average Exercise Price, Outstanding beginning balance | $ / shares	$ 1.51
Shares, Granted | shares
Weighted- Average Exercise Price, Granted | $ / shares
Shares, Vested | shares	(4,598,334)
Weighted- Average Exercise Price, Vested | $ / shares	$ 1.5
Shares, Forfeited | shares
Weighted- Average Exercise Price, Forfeited | $ / shares
Shares, Nonvested at ending balance | shares	30,000
Weighted- Average Exercise Price, Outstanding ending balance | $ / shares	$ 1.92

Stockholders_ Equity (Details_3

Stockholders’ Equity (Details) - Schedule of stock option granted was estimated using the Black-Scholes assumption - Equity Option [Member]	3 Months Ended
	Mar. 31, 2022$ / shares
Stockholders’ Equity (Details) - Schedule of stock option granted was estimated using the Black-Scholes assumption [Line Items]
Exercise price (in Dollars per share)	$ 4
Expected dividend yield	0.00%
Minimum [Member]
Stockholders’ Equity (Details) - Schedule of stock option granted was estimated using the Black-Scholes assumption [Line Items]
Risk free interest rate	0.17%
Expected life in years	3 years
Expected volatility	154.00%
Maximum [Member]
Stockholders’ Equity (Details) - Schedule of stock option granted was estimated using the Black-Scholes assumption [Line Items]
Risk free interest rate	0.42%
Expected life in years	5 years
Expected volatility	159.00%

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	May 14, 2022	Apr. 04, 2022
Subsequent Events (Details) [Line Items]
Revenue of aggregate amount		$ 30
Warrant exercisabe term	The Warrants have an exercise price of $0.33 per share and are exercisable for a term of five years commencing six months from the date of closing.
Warrant exercise price	$ 0.33
Securities Purchase Agreement [Member] | Common Stock [Member]
Subsequent Events (Details) [Line Items]
Sale of stock	8,333,334
Purchase price per share	$ 0.3
Gross proceeds	$ 2,500,000